Red X iconGreen tick iconYellow tick icon

Professor Shyamal Das

Contact Details

Phone
+64 3 479 4262
Email
shyamal.das@otago.ac.nz
Position
Professor and Associate Dean (Research)
Qualifications
MPharm PhD
Research summary
Drug formulation and delivery, drug delivery to the lung
Teaching

Teaching

  • PHCY 211 Fundamental Pharmaceutical Sciences
  • PHCY 220 Integrated modules A
  • PHCY 310 Integrated modules B
  • PHCY 430 Elective Projects B
  • PHCY 480 Honours Research Project
  • PHCY 485 Applied Pharmacotherapy and Patient Care for Honours
  • PSCI 204 Formulation Principles 2
  • PSCI 305 Drug Delivery
  • Inter Professional education

Co-ordination

  • Programme Co-ordinator for BPharm(Hons) programme
  • PHCY 480 Honours Research Project (Course Co-ordinator)
  • PHCY 485 Applied Pharmacotherapy and Patient Care for Honours (Course Co-ordinator)
  • PSCI 305 Drug Delivery
Memberships
  • Editorial Board: International Journal of Pharmaceutics (Q1, 16th/171 journals in pharmaceutical science, Citescore: 9.6 (Scopus 2021) (2018 to present)
  • Guest editor, International Journal of Pharmaceutics special issue on ‘The respiratory delivery of high dose powders’ (2018) and 'in honor of Ian Tucker' (2021 to 2022)
  • Editorial Board Member, Pharmaceutics (2022 to present)
  • Associate Editor, Frontiers Drug Delivery Pulmonary Drug Delivery (2021 to present)
  • Scientific Advisory Committee member, Drug Delivery to the Lung Conference (2015 to Present)
  • The Aerosol Society (2013 to present)
  • Australasian Pharmaceutical Science Association (APSA) (2006 to present)
  • Otago Medical School Research Society: President (2023 to 2024), Vice-President (2021 to 2022), Treasurer (2019 to present), Executive Committee Member (2018)
  • New Zealand Chapter of the Controlled Release Society (2013 to present): President Elect (2021 to present), Treasurer (2019 to 2021), Executive Committee Member (2017 to 2019)
  • Otago Global Health Institute: Profiled Network Member (2016 to present)
  • Associate Invesigator, Maurice Wilkins Centre (2022 to present)

Research

The research interests of Professor Das revolve around drug delivery, in particular, respiratory drug delivery of powder formulations for treating chronic lung conditions such as COPD, asthma, tuberculosis, lung cancer and lung infections.

His aim is to achieve a fundamental knowledge base on solid state characterisation processes to understand various pharmaceutical processes such as milling, mixing, spray drying, amorphisation, micronisation, crystallisation, relaxation, dissolution, coating and storage. These knowledge and innovating approaches can be used to develop various conventional and controlled release solid dosage forms such as powders for respiratory delivery as well as tablets and capsules for oral delivery.

Professor Das has extensive research networks with collaborators in New Zealand, Australia, Europe, Asia, the United Kingdom and the USA.
For more visit Das laboratory

PhD projects available

Please contact me if you are interested in conducting PhD research in the following areas:

  • Interactions and influence of lung surfactant on dissolution in the lung
  • Solid surface characteristics that influence powder delivery to the lung

Biography

Professor Shyamal Das lectures in Pharmaceutical Science at the School of Pharmacy, University of Otago. He is an internationally recognised formulation expert with over 15 years of experience in dry powder inhaler technology.

Professor Das supervises a large productive research group which focuses on drug delivery to the lung to improve therapy for chronic lung conditions such as asthma, chronic obstructive pulmonary disease, cystic fibrosis and tuberculosis. He is currently contributing to the development of inhalers to treat coronaviruses in collaboration with academia and industries.

Professor Das completed his PhD and research fellowships at Monash Institute of Pharmaceutical Sciences. He was a visiting researcher at the University College London (UK), Imperial College London (UK) and the University of Texas at Austin (USA).

Professor Das is also an award-winning passionate lecturer. He has won multiple awards for best teaching and supervision at the University of Otago.

Additional details

Previous positions

  • Research Fellow, Monash Institute of Pharmaceutical Sciences, Monash University, Australia (2008–2013)
  • Teaching Assistant, Department of Pharmaceutics and Department of Pharmacy Practice, Monash University, Australia (2005–2008)
  • Assistant Professor, Department of Pharmacy, Jahangirnagar University, Bangladesh (2003–2004)
  • Lecturer, Department of Pharmacy, Jahangirnagar University, Bangladesh (2000–2003)

Teaching and research awards

  • United Kingdom Council for Graduate Education (UKCGE) Recognised Research Supervisor 2022
  • Winner of the School of Pharmacy (SOP) Best Research Paper Award 2021, 2020 and 2019
  • Winner of the Otago University Students’ Association’s 2017 Teaching Excellence Award: Premier Lecturer Award 2017 Division of Health Sciences
  • Winner of the Otago University Students’ Association’s Supervisor of the Year Award 2017 Division of Health Sciences
  • Winner of the School of Pharmacy’s Excellence in Teaching Award 2016
  • Winner of the Otago University Students’ Association’s 2016 Teaching Excellence Award (Top Five Teacher)
  • Winner of the Otago School of Pharmacy’s Emerging Researcher Award 2016
  • Finalist (top five) for the Australasian Pharmaceutical Scientists Association’s 2016 Early Career Investigator Award
  • Health Research Council of New Zealand’s Emerging Researcher First Grant 2015

School of Pharmacy administrative roles

  • Associate Dean Research (August 2021- Present)
  • School’s representative to Division of Health Science Research Committee
  • Chair, BPharm(Hons) Committee (since 2014)
  • Co-Chair, School of Pharmacy Research Committee (since 2020) and Member since February 2017)
  • Member, Research and Postgraduate Committee (since March 2019)
  • Member, School of Pharmacy Undergraduate Programmes Committee
  • Member, School of Pharmacy BPharm/BPharm(Hons) Curriculum Committee (since November 2017)
  • Self-Review Coordinator of BPharm(Hons) Programme (2018)
  • Member, School of Pharmacy Admission Working Party (June 2016 to June 2018)

Publications

Khadka, P., Dummer, J., Hill, P. C., & Das, S. C. (2024). The quest to deliver high-dose rifampicin: Can the inhaled approach help? [Review]. Expert Opinion on Drug Delivery, 21(1), 31-44. doi: 10.1080/17425247.2024.2301931

Saha, T., Lyons, N., Yung, D. B. Y., Quiñones‑Mateu, M. E., Pletzer, D., & Das, S. C. (2024). Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics & Biopharmaceutics, 195, 114170. doi: 10.1016/j.ejpb.2023.12.010

Eedara, B. B., Fan, C., Sinha, S., Khadka, P., & Das, S. C. (2023). Inhalable combination powder formulations for treating latent and multidrug-resistant tuberculosis: Formulation and in vitro characterization. Pharmaceutics, 15, 2354. doi: 10.3390/pharmaceutics15092354

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection. Pharmaceutics, 15, 2229. doi: 10.3390/pharmaceutics15092229

Das, S. C., Khadka, P., Shah, R., McGill, S., & Smyth, H. D. C. (2021). Nanomedicine in pulmonary delivery. In P. Kesharwani, S. Taurin & K. Greish (Eds.), Theory and applications of nonparenteral nanomedicines. (pp. 319-354). London, UK: Elsevier. doi: 10.1016/B978-0-12-820466-5.00014-4

Chapter in Book - Research

Hadjittofis, E., Das, S. C., Zhang, G. G. Z., & Heng, J. Y. Y. (2017). Interfacial phenomena. In Y. Qiu, Y. Chen, G. G. Z. Zhang, L. Yu & R. V. Mantri (Eds.), Developing solid oral dosage forms: Pharmaceutical theory & practice. (2nd ed.) (pp. 225-252). London, UK: Academic Press. doi: 10.1016/B978-0-12-802447-8.00008-X

Chapter in Book - Research

Das, S. C., & Stewart, P. J. (2016). Understanding the respiratory delivery of high dose anti-tubercular drugs. In A. J. Hickey, A. Misra & P. B. Fourie (Eds.), Drug delivery systems for tuberculosis prevention and treatment. (pp. 258-274). Chichester, UK: Wiley. doi: 10.1002/9781118943182.ch13

Chapter in Book - Research

Saha, T., Lyons, N., Yung, D. B. Y., Quiñones‑Mateu, M. E., Pletzer, D., & Das, S. C. (2024). Repurposing ebselen as an inhalable dry powder to treat respiratory tract infections. European Journal of Pharmaceutics & Biopharmaceutics, 195, 114170. doi: 10.1016/j.ejpb.2023.12.010

Journal - Research Article

Eedara, B. B., Fan, C., Sinha, S., Khadka, P., & Das, S. C. (2023). Inhalable combination powder formulations for treating latent and multidrug-resistant tuberculosis: Formulation and in vitro characterization. Pharmaceutics, 15, 2354. doi: 10.3390/pharmaceutics15092354

Journal - Research Article

Khadka, P., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2023). A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation. Drug Delivery & Translational Research, 13, 1246-1271. doi: 10.1007/s13346-022-01238-y

Journal - Research Article

Khadka, P., Tucker, I. G., & Das, S. C. (2023). In vitro dissolution testing of rifampicin powder formulations for prediction of plasma concentration-time profiles after inhaled delivery. Pharmaceutical Research, 40, 1153-1163. doi: 10.1007/s11095-022-03439-z

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Inhalable dry powder containing remdesivir and disulfiram: Preparation and in vitro characterization. International Journal of Pharmaceutics, 645, 123411. doi: 10.1016/j.ijpharm.2023.123411

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones‑Mateu, M. E., & Das, S. C. (2023). Spray-dried inhalable microparticles combining remdesivir and ebselen against SARS-CoV-2 infection. Pharmaceutics, 15, 2229. doi: 10.3390/pharmaceutics15092229

Journal - Research Article

Adhikari, B. R., & Das, S. C. (2022). Amorphicity and aerosolization of soluplus-based inhalable spray dried powders. Pharmaceutics, 14(12), 2618. doi: 10.3390/pharmaceutics14122618

Journal - Research Article

Adhikari, B. R., Bērziņš, K., Fraser-Miller, S. J., Cavallaro, A., Gordon, K. C., & Das, S. C. (2022). Optimization of methionine in inhalable high-dose spray-dried amorphous composite particles using response surface method, infrared and low frequency Raman spectroscopy. International Journal of Pharmaceutics, 614, 121446. doi: 10.1016/j.ijpharm.2021.121446

Journal - Research Article

Adhikari, B. R., Dummer, J., Gordon, K. C., & Das, S. C. (2022). An expert opinion on respiratory delivery of high dose powders for lung infections. Expert Opinion on Drug Delivery, 19(7), 795-813. doi: 10.1080/17425247.2022.2089111

Journal - Research Article

Adhikari, B. R., Gordon, K. C., & Das, S. C. (2022). Solid state of inhalable high dose powders. Advanced Drug Delivery Reviews, 189, 114468. doi: 10.1016/j.addr.2022.114468

Journal - Research Article

Adhikari, B. R., Sinha, S., Gordon, K. C., & Das, S. C. (2022). Amino acids improve aerosolization and chemical stability of potential inhalable amorphous spray-dried ceftazidime for Pseudomonas aeruginosa lung infection. International Journal of Pharmaceutics, 621, 121799. doi: 10.1016/j.ijpharm.2022.121799

Journal - Research Article

Adhikari, B. R., Sinha, S., Lyons, N., Pletzer, D., Lamont, I., Gordon, K. C., & Das, S. C. (2022). Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation. European Journal of Pharmaceutics & Biopharmaceutics, 180, 260-268. doi: 10.1016/j.ejpb.2022.10.005

Journal - Research Article

Eedara, B. B., Bastola, R., & Das, S. C. (2022). Dissolution and absorption of inhaled drug particles in the lungs [Review]. Pharmaceutics, 14, 2667. doi: 10.3390/pharmaceutics14122667

Journal - Research Article

Saha, T., Quiñones‑Mateu, M. E., & Das, S. C. (2022). Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices. International Journal of Pharmaceutics, 624, 122042. doi: 10.1016/j.ijpharm.2022.122042

Journal - Research Article

Saha, T., Sinha, S., Harfoot, R., Quiñones Mateu, M. E., & Das, S. C. (2022). Manipulation of spray-drying conditions to develop an inhalable ivermectin dry powder. Pharmaceutics, 14(7), 1432. doi: 10.3390/pharmaceutics14071432

Journal - Research Article

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats. European Journal of Pharmaceutics & Biopharmaceutics, 162, 1-11. doi: 10.1016/j.ejpb.2021.02.011

Journal - Research Article

Khadka, P., Sinha, S., Tucker, I. G., Dummer, J., Hill, P. C., Katare, R., & Das, S. C. (2021). Studies on the safety and the tissue distribution of inhaled high-dose amorphous and crystalline rifampicin in a rat model. International Journal of Pharmaceutics, 597, 120345. doi: 10.1016/j.ijpharm.2021.120345

Journal - Research Article

Momin, M. A. M., Adhikari, B. R., Sinha, S., Larson, I., & Das, S. C. (2021). Roflumilast powders for chronic obstructive pulmonary disease: Formulation design and the influence of device, inhalation flow rate, and storage relative humidity on aerosolization. Pharmaceutics, 13, 1254. doi: 10.3390/pharmaceutics13081254

Journal - Research Article

Adhikari, B. R., Bērziņš, K., Fraser-Miller, S. J., Gordon, K. C., & Das, S. C. (2020). Co-amorphization of kanamycin with amino acids improves aerosolization. Pharmaceutics, 12(8), 715. doi: 10.3390/pharmaceutics12080715

Journal - Research Article

Khadka, P., Hill, P. C., Zhang, B., Katare, R., Dummer, J., & Das, S. C. (2020). A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment. International Journal of Pharmaceutics, 587, 119602. doi: 10.1016/j.ijpharm.2020.119602

Journal - Research Article

Eedara, B. B., Tucker, I. G., & Das, S. C. (2019). In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. International Journal of Pharmaceutics, 559, 235-244. doi: 10.1016/j.ijpharm.2019.01.035

Journal - Research Article

Eedara, B. B., Tucker, I. G., & Das, S. C. (2019). A STELLA simulation model for in vitro dissolution testing of respirable size particles. Scientific Reports, 9(1), 18522. doi: 10.1038/s41598-019-55164-0

Journal - Research Article

Eedara, B. B., Tucker, I. G., Zujovic, Z. D., Rades, T., Price, J. R., & Das, S. C. (2019). Crystalline adduct of moxifloxacin with trans-cinnamic acid to reduce the aqueous solubility and dissolution rate for improved residence time in the lungs. European Journal of Pharmaceutical Sciences, 136, 104961. doi: 10.1016/j.ejps.2019.104961

Journal - Research Article

Momin, M. A. M., Rangnekar, B., Larson, I., Sinha, S., & Das, S. C. (2019). Dry powder formulation combining bedaquiline with pyrazinamide for latent and drug-resistant tuberculosis. Advanced Powder Technology, 30(11), 2473-2482. doi: 10.1016/j.apt.2019.07.016

Journal - Research Article

Momin, M. A. M., Rangnekar, B., Sinha, S., Cheung, C.-Y., Cook, G. M., & Das, S. C. (2019). Inhalable dry powder of Bedaquiline for pulmonary tuberculosis: In vitro physiochemical characterization, antimicrobial activity and safety studies. Pharmaceutics, 11(10), 502. doi: 10.3390/pharmaceutics11100502

Journal - Research Article

Momin, M. A. M., Sinha, S., Tucker, I. G., & Das, S. C. (2019). Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis. Drug Development & Industrial Pharmacy, 45(8), 1321-1331. doi: 10.1080/03639045.2019.1609494

Journal - Research Article

Momin, M. A. M., Tucker, I. G., & Das, S. C. (2019). The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin. Drug Development & Industrial Pharmacy, 45(7), 1205-1213. doi: 10.1080/03639045.2019.1607869

Journal - Research Article

Rangnekar, B., Momin, M. A. M., Eedara, B. B., Sinha, S., & Das, S. C. (2019). Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis. International Journal of Pharmaceutics, 570, 118689. doi: 10.1016/j.ijpharm.2019.118689

Journal - Research Article

Eedara, B. B., Rangnekar, B., Doyle, C., Cavallaro, A., & Das, S. C. (2018). The influence of surface active L-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders. International Journal of Pharmaceutics, 542(1-2), 72-81. doi: 10.1016/j.ijpharm.2018.03.005

Journal - Research Article

Khadka, P., Dummer, J., Hill, P. C., & Das, S. C. (2018). Considerations in preparing for clinical studies of inhaled rifampicin to enhance tuberculosis treatment. International Journal of Pharmaceutics, 548(1), 244-254. doi: 10.1016/j.ijpharm.2018.07.011

Journal - Research Article

Momin, M. A. M., Rangnekar, B., & Das, S. C. (2018). Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation. Journal of Liquid Chromatography & Related Technologies, 41(8), 415-421. doi: 10.1080/10826076.2018.1437748

Journal - Research Article

Momin, M. A. M., Tucker, I. G., & Das, S. C. (2018). High dose dry powder inhalers to overcome the challenges of tuberculosis treatment. International Journal of Pharmaceutics, 550(1-2), 398-417. doi: 10.1016/j.ijpharm.2018.08.061

Journal - Research Article

Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., & Das, S. C. (2018). Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug. International Journal of Pharmaceutics, 543, 318-327. doi: 10.1016/j.ijpharm.2018.04.003

Journal - Research Article

Momin, M. A. M., Tucker, I. G., Doyle, C. S., Denman, J. A., Sinha, S., & Das, S. C. (2018). Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections. International Journal of Pharmaceutics, 541(1-2), 26-36. doi: 10.1016/j.ijpharm.2018.02.026

Journal - Research Article

Momin, M. A. M., Sinha, S., Tucker, I. G., Doyle, C., & Das, S. C. (2017). Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis. International Journal of Pharmaceutics, 528(1-2), 107-117. doi: 10.1016/j.ijpharm.2017.06.004

Journal - Research Article

Momin, M. A. M., Thien, S. J., Krittaphol, W., & Das, S. C. (2017). Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of Pharmaceutical & Biomedical Analysis, 135, 133-139. doi: 10.1016/j.jpba.2016.11.046

Journal - Research Article

Das, S. C., & Stewart, P. J. (2016). The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery. International Journal of Pharmaceutics, 514(2), 465-474. doi: 10.1016/j.ijpharm.2016.06.029

Journal - Research Article

Eedara, B. B., Tucker, I. G., & Das, S. C. (2016). Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis. International Journal of Pharmaceutics, 506(1-2), 174-183. doi: 10.1016/j.ijpharm.2016.04.038

Journal - Research Article

Das, S. C., Tucker, I. G., & Stewart, P. J. (2015). Surface energy determined by inverse gas chromatography as a tool to investigate particulate interactions in dry powder inhalers. Current Pharmaceutical Design, 21(27), 3932-3944. Retrieved from http://europepmc.org/abstract/MED/26290201

Journal - Research Article

Das, S., Tucker, I., & Stewart, P. (2015). Inhaled dry powder formulations for treating tuberculosis. Current Drug Delivery, 12(1), 26-39.

Journal - Research Article

Shi, J., Das, S., Morton, D., & Stewart, P. (2015). The kinetics of de-agglomeration of magnesium stearate dry-coated salbutamol sulphate powders. KONA Powder & Particle Journal, (32), 131-142. doi: 10.14356/kona.2015001

Journal - Research Article

Tucker, I. G., Das, S. C., & Stewart, P. J. (2015). A view on the less-than-rational development of drug delivery systems: The example of dry powder inhalers. Journal of Drug Delivery Science & Technology, 30, 310-317. doi: 10.1016/j.jddst.2015.06.008

Journal - Research Article

Allahham, A., Stewart, P. J., & Das, S. C. (2013). Improving the de-agglomeration and dissolution of a poorly water soluble drug by decreasing the agglomerate strength of the cohesive powder. International Journal of Pharmaceutics, 457(1), 101-109. doi: 10.1016/j.ijpharm.2013.09.030

Journal - Research Article

Das, S. C., Behara, S. R. B., Morton, D. A. V., Larson, I., & Stewart, P. J. (2013). Importance of particle size and shape on the tensile strength distribution and de-agglomeration of cohesive powders. Powder Technology, 249, 297-303. doi: 10.1016/j.powtec.2013.08.034

Journal - Research Article

Das, S. C., & Stewart, P. J. (2012). Characterising surface energy of pharmaceutical powders by inverse gas chromatography at finite dilution. Journal of Pharmacy & Pharmacology, 64(9), 1337-1348. doi: 10.1111/j.2042-7158.2012.01533.x

Journal - Research Article

Das, S. C., Behara, S. R. B., Bulitta, J. B., Morton, D. A. V., Larson, I., & Stewart, P. J. (2012). Powder strength distributions for understanding de-agglomeration of lactose powders. Pharmaceutical Research, 29(10), 2926-2935. doi: 10.1007/s11095-012-0799-0

Journal - Research Article

Das, S. C., Larson, I., Morton, D. A. V., & Stewart, P. J. (2011). Determination of the polar and total surface energy distributions of particulates by inverse gas chromatography. Langmuir, 27(2), 521-523. doi: 10.1021/la104135z

Journal - Research Article

Das, S. C., Zhou, Q., Morton, D. A. V., Larson, I., & Stewart, P. J. (2011). Use of surface energy distributions by inverse gas chromatography to understand mechanofusion processing and functionality of lactose coated with magnesium stearate. European Journal of Pharmaceutical Sciences, 43(4), 325-333. doi: 10.1016/j.ejps.2011.05.012

Journal - Research Article

Zhou, Q., Denman, J. A., Gengenbach, T., Das, S., Qu, L., Zhang, H., … Morton, D. A. V. (2011). Characterization of the surface properties of a model pharmaceutical fine powder modified with a pharmaceutical lubricant to improve flow via a mechanical dry coating approach. Journal of Pharmaceutical Sciences, 100(8), 3421-3430. doi: 10.1002/jps.22547

Journal - Research Article

Das, S., Larson, I., Young, P., & Stewart, P. (2010). Understanding lactose behaviour during storage by monitoring surface energy change using inverse gas chromatography. Dairy Science & Technology, 90(2-3), 271-285. doi: 10.1051/dst/2009051

Journal - Research Article

Tay, T., Das, S., & Stewart, P. (2010). Magnesium stearate increases salbutamol sulphate dispersion: What is the mechanism? International Journal of Pharmaceutics, 383(1-2), 62-69. doi: 10.1016/j.ijpharm.2009.09.006

Journal - Research Article

Das, S., Larson, I., Young, P., & Stewart, P. (2009). Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. European Journal of Pharmaceutical Sciences, 37(3-4), 442-450. doi: 10.1016/j.ejps.2009.03.016

Journal - Research Article

Das, S., Larson, I., Young, P., & Stewart, P. (2009). Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation. Journal of Pharmaceutical Sciences, 98(3), 1015-1027. doi: 10.1002/jps.21500

Journal - Research Article

Das, S., Larson, I., Young, P., & Stewart, P. (2009). Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. European Journal of Pharmaceutical Sciences, 38(4), 347-354. doi: 10.1016/j.ejps.2009.08.007

Journal - Research Article

Khadka, P., Dummer, J., Hill, P. C., & Das, S. C. (2024). The quest to deliver high-dose rifampicin: Can the inhaled approach help? [Review]. Expert Opinion on Drug Delivery, 21(1), 31-44. doi: 10.1080/17425247.2024.2301931

Journal - Research Other

Das, S., Rades, T., & McDowell, A. (2023). In honor of Professor Ian Tucker. International Journal of Pharmaceutics. Advance online publication. doi: 10.1016/j.ijpharm.2023.122762

Journal - Research Other

Ameratunga, R., Woon, S.-T., Steele, R., Snell, R., Medlicott, N., Mears, E., … Das, S., … Quiñones‑Mateu, M. E. (2021). The nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection. Expert Review of Clinical Immunology, 17(6), 553-560. doi: 10.1080/1744666x.2021.1912596

Journal - Research Other

Bastola, R., Young, P. M., & Das, S. C. (2021). Simulation of respiratory tract lining fluid for in vitro dissolution study. Expert Opinion on Drug Delivery, 18(8), 1091-1100. doi: 10.1080/17425247.2021.1882991

Journal - Research Other

Saha, T., Khadka, P., & Das, S. C. (2021). Alcohol-based hand sanitizer: Composition, proper use and precautions. Germs, 11(3), 408-417. doi: 10.18683/germs.2021.1278

Journal - Research Other

Ameratunga, R., Lehnert, K., Leung, E., Comoletti, D., Snell, R., Woon, S.-T., … Medlicott, N., Das, S., … Quiñones‑Mateu, M., … Jordan, A. (2020). Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. New Zealand Medical Journal, 133(1515), 112-118. Retrieved from https://www.nzma.org.nz/journal

Journal - Research Other

Das, S. C., Stewart, P. J., & Tucker, I. G. (2018). The respiratory delivery of high dose dry powders. International Journal of Pharmaceutics, 550, 486-487. doi: 10.1016/j.ijpharm.2018.09.014

Journal - Research Other

Back to top